Literature DB >> 15687478

QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.

Diane L Nykamp1, Casey L Blackmon, Paul E Schmidt, Andrea G Roberson.   

Abstract

OBJECTIVE: To report QTc interval prolongation associated with combination therapy including levofloxacin, imipramine, and fluoxetine. CASE
SUMMARY: A 49-year-old white female presented to the emergency department with fever, aches, and pains for the past 3 days. She was diagnosed and treated for pyelonephritis in the hospital. Therapy included intravenous levofloxacin 500 mg every 24 hours and ceftriaxone 2 g every 24 hours, along with her medications upon admission, including imipramine 50 mg at bedtime and fluoxetine 10 mg/day. She was discharged after 5 days and returned the next day with chest tightness and shortness of breath. Upon the second admission, a 12-lead electrocardiogram showed a QTc interval of 509 msec. Levofloxacin was discontinued and the QTc interval fell to 403 msec. The patient was discharged 3 days later and instructed to consult with her primary care physician about discontinuing imipramine. DISCUSSION: This adverse drug reaction is thought to be a pharmacodynamic additive effect among fluoxetine, imipramine, and levofloxacin. Fluoxetine is a potent inhibitor of CYP2D6, and imipramine is metabolized by CYP2D6. Therefore, fluoxetine is able to increase the plasma concentrations of imipramine, leading to QT interval prolongation. Taken with imipramine, levofloxacin can lead to even greater prolongation of the QT interval. Based on the Naranjo probability scale, levofloxacin was possibly associated with cardiac arrhythmias in our patient.
CONCLUSIONS: The use of levofloxacin alone, or more often in concomitant therapy with other medications that are known to prolong the QT interval, may cause QT interval prolongation; however, additional studies/case reports are needed to validate this conclusion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15687478     DOI: 10.1345/aph.1E513

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  10 in total

Review 1.  The QT interval and psychotropic medications in children: recommendations for clinicians.

Authors:  Paul McNally; Fiona McNicholas; Paul Oslizlok
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-08-29       Impact factor: 4.785

2.  Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.

Authors:  Qasim Khan; Mohammad Ismail; Iqbal Haider; Fahadullah Khan
Journal:  Int J Clin Pharm       Date:  2017-09-12

3.  Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.

Authors:  S Rajamani; L L Eckhardt; C R Valdivia; C A Klemens; B M Gillman; C L Anderson; K M Holzem; B P Delisle; B D Anson; J C Makielski; C T January
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

Review 4.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

Review 5.  Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Authors:  Zhiqiang Kevin Lu; Jing Yuan; Minghui Li; S Scott Sutton; Gowtham A Rao; Sony Jacob; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2014-12-10       Impact factor: 4.250

Review 6.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

7.  Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis.

Authors:  Einat Gorelik; Reem Masarwa; Amichai Perlman; Victoria Rotshild; Momen Abbasi; Mordechai Muszkat; Ilan Matok
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

8.  Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology.

Authors:  J C Hancox; J S Mitcheson
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

9.  Analysis of Relationship between Levofloxacin and Corrected QT Prolongation Using a Clinical Data Warehouse.

Authors:  Man Young Park; Eun Yeob Kim; Young Ho Lee; Woojae Kim; Ku Sang Kim; Seung Soo Sheen; Hong Seok Lim; Rae Woong Park
Journal:  Healthc Inform Res       Date:  2011-03-31

Review 10.  QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature.

Authors:  Anhua Wei; Jinlan Peng; Zhichun Gu; Juan Li
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.